Adamax
Adamantyl-Semax analogue
neuroplasticity
learning
memory
mental clarity
focus
neuroprotection
motivation
low mood
A Semax molecule with an adamantane cage bolted on, sold on the claim that the change makes it last longer and push BDNF harder. Almost nothing about it has been published.
Goal profile
BRAIN
6/8 axes
MOOD
2/8 axes
Evidence
2010
first described
6
indexed studies
How strong the evidence is
Cell and theory only
Six papers, none of them a human trial. The molecule is a Semax analogue and everything claimed for it is inferred from Semax plus a chemical argument about why the adamantane cage should make it last longer. Inference is not evidence.
Highest study design
cell and theory
Human studies
none
Replication
one group only
Regulatory status
not approved anywhere
Last reviewed
2026-09-22
The bar is derived from these five facts, not set by hand. Human study counts follow the weekly PubMed refresh; the rest change only when a trial is published or a regulator acts.
How strong the effect is
strength 2 of 5 · weight 0.45
Noticeable but modest
Six papers, no human trial. The claim that the adamantane version outperforms plain Semax rests on vendor copy, not on data.
What's unique
The adamantane cage is the whole idea: same Semax backbone, but harder for enzymes to chew through, so one dose is claimed to work longer and lean harder on BDNF.
Unexpected positive evidence
What people report is not sharper focus but looser association — ideas arriving sideways. Nothing in the literature was designed to measure that, which is exactly why it should be treated as anecdote.
Benefits
BDNF pushed harder and for longer than plain Semax — the entire argument for the molecule, and it rests on chemistry rather than on a trial
Neuroplasticity · immediate
new material sticking after fewer passes, reported by people who were learning something while they took it
Learning · immediate
recall of detail holding up through long working days
Memory · from week 2
looser association — ideas arriving sideways rather than in a line; the effect people take it for and the one nobody has measured
Mental clarity · from week 3
attention widening rather than narrowing, which is the opposite of what a stimulant does
Focus · from week 3
the neuroprotective claim inherited from Semax, untested in this modified form
Neuroprotection · from week 4
more willingness to start work that has no clear end, reported alongside the cognitive changes
Motivation · from week 4
Timeline
Days 1–5
Most people feel something in the first days — which with a peptide this thinly studied is worth suspicion, not celebration. Usually described as a slight lift and a wider peripheral attention. Irritability and a short night if the dose lands late.
Weeks 1–2
The reported effect settles into its shape: not focus but looseness. Connections arriving from the side, more willingness to start something unfinished. This is anecdote from a small number of people, and it is the least measured claim in this app.
Weeks 3–6
Whatever showed up in week two tends to hold at the same level rather than build. If it has not appeared by now it is not going to — the honest read at week three is that this molecule does nothing for you.
After the course
No withdrawal described. The looseness fades over a couple of weeks. Four weeks clear before any second course: with no human safety data, the pause is the only protection there is.
Risks
Short-term
Overstimulation, irritability and broken sleep if dosed late. The looseness some people want reads as scatter to others.
Long-term
No human safety data at all. Six papers exist and none of them followed anyone for long. Treat the long term as unknown, not as safe.
Tolerance & withdrawal
Five days on, two off — the same pattern Semax needs, and for the same reason: the receptors stop answering.
Dosing
Dose
125–500 mcg
Nobody has established a dose. 250 mcg is what the vendors print and what the forums copy — start at half of it.
Route
Subcutaneous — abdomen
A small volume into the belly, sites rotated across the course.
Timing
Morning, before noon
Mornings. Dosed late it costs you the night, and the night is where the day’s work settles.
Frequency
Five days on, two off
Five days on, two off. The receptors stop answering on continuous use — the same ceiling plain Semax runs into.
Cycle
6 weeks on, 4 off
Six weeks, then a month clear. There is no long-term data to lean on, so the pause is the safety margin.
Duration
Short courses only
Treat anything past six weeks as untested. With six papers behind the molecule, that is not caution — it is the whole picture.
Forms
injectable
~100%
+ Full dose delivered; nothing lost to first-pass
− Daily needles, sites, sharps disposal
Refrigerate 2–8 °C after reconstitution
Sources
6 indexed papers in the source catalog snapshot; not a live PubMed count
Catalog evidence category: theoretical. This is an editorial classification, not a clinical review.
Community anecdotes do not establish safety or efficacy.
Primary regulatory sources are linked below; clinical literature has not been independently reviewed for this FAQ.
FAQ
Adamax (Adamantyl-Semax analogue) is a heptapeptide (modified). The HEIVE catalog describes it as: A Semax molecule with an adamantane cage bolted on, sold on the claim that the change makes it last longer and push BDNF harder. Almost nothing about it has been published. It is also known as N-adamantyl-Semax and Adamax peptide.
Regulatory sources checked: . Source verification only; no clinician review is claimed.